The purpose of the study is (1) to identify and collect samples from children and adults who take drugs and have adverse drug reactions AND children and adults who take drugs and do not experience any adverse drug effects; (2) to determine if genetic differences between the two groups contribute to causing the adverse drug reactions; and (3) to develop patient specific drug dosing guidelines to prevent future adverse drug reactions. We also wish to compare the use of prescription drugs, medical and hospital services and vital statistics between BC participants who experience adverse drug reactions and those who do not.
Study hypothesis: Genetic differences may contribute to patients' response to drugs and may be responsible for adverse drug reactions.
Children under 19 years who have taken drugs.
Biological parents of children who have had an ADR.
Patients/parents who speak and understand English (except in Quebec).
Adults (for validation of findings in children)
None
Children under 19 years who have taken drugs and adults to replicate findings in children
Cohort
Other
Not listed
Determine the role of genetic and clinical factors in adverse drug reactions to develop risk mitigation strategies.
Click on the lead sponsor to view all of their trials.
University of British Columbia
Lead sponsor
Genome Canada
Collaborator
Genome British Columbia
Collaborator
Child and Family Research Institute
Collaborator
Western University, Canada
Collaborator
Provincial Health Services Authority British Columbia
Collaborator
Health Canada
Collaborator
Canada Gene Cure
Collaborator
Eli Lilly and Company
Collaborator
Pfizer
Collaborator
Merck Sharp & Dohme LLC
Collaborator
Canadian Society of Clinical Pharmacology
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator
Canada Foundation for Innovation
Collaborator
British Columbia Clinical Genomics Network
Collaborator
